Title	Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin
Author(s)	Miyashita, Kazuo; Beppu, Fumiaki; Hosokawa, Masashi; Liu, Xiaoyong; Wang, Shuzhou
Citation	Archives of biochemistry and biophysics, 686, 108364 https://doi.org/10.1016/j.abb.2020.108364
Issue Date	2020-06-15
Doc URL	http://hdl.handle.net/2115/81864
Rights	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
Rights(URL)	https://creativecommons.org/licenses/by-nc-nd/4.0/
Type	article (author version)
File Information	manuscript received 2020-06-10.pdf

[Instructions for use](#)

1 Nutraceutical characteristics of the brown seaweed carotenoid fucoxanthin

2
3 Kazuo Miyashita^{1*}, Fumiaki, Beppu¹, Masashi Hosokawa¹, Xiaoyong Liu², Shuzhou
4 Wang²

5
6 ¹Faculty of Fisheries Sciences, Hokkaido University, Hakodate 041-8611, Japan

7 ²Shandong Haizhibao Ocean Science and Technology Co., Ltd., Rongcheng City
8 264300, China

9
10 *Correspondence to: Kazuo Miyashita, Faculty of Fisheries Sciences, Hokkaido
11 University, Hakodate 041-8611, Japan.

12 E-mail: kmiya@fish.hokudai.ac.jp

13
14
15 **ABSTRACT**

16 Fucoxanthin (Fx), a major carotenoid found in brown seaweed, is known to show a
17 unique and wide variety of biological activities. Upon absorption, Fx is metabolized to
18 fucoxanthinol and amarouciaxanthin, and these metabolites mainly accumulate in
19 visceral white adipose tissue (WAT). As seen in other carotenoids, Fx can quench
20 singlet oxygen and scavenge a wide range of free radicals. The antioxidant activity is
21 related to the neuroprotective, photoprotective, and hepatoprotective effects of Fx. Fx is
22 also reported to show anti-cancer activity through the regulation of several biomolecules
23 and signaling pathways that are involved in either cell cycle arrest, apoptosis, or
24 metastasis suppression. Among the biological activities of Fx, anti-obesity is the most
25 well-studied and most promising effect. This effect is primarily based on the
26 upregulation of thermogenesis by uncoupling protein 1 expression and the increase in
27 the metabolic rate induced by mitochondrial activation. In addition, Fx shows
28 anti-diabetic effects by improving insulin resistance and promoting glucose utilization
29 in skeletal muscle.

30
31 *Keywords:* Brown seaweeds, Fucoxanthin, Anti-obesity, Anti-diabetes, Anti-cancer

32
33 **1. Introduction**

34
35 Seaweeds (marine macroalgae) are photosynthesizing plants that form the basic
36 biomass in the intertidal zone. They are a varied group, with sizes ranging from a few

centimeters to 100 m in length. According to their color, they are divided into three main classes: green (chlorophytes), red (rhodophytes), and brown (phaeophytes). Brown seaweeds are the most consumed species, followed by red and green seaweeds [1]. As seaweeds lack many of the distinct organs (roots, stems, leaves) found in terrestrial plants, whole parts can be used as a source of food, cosmetics, and other products. They have high nutritional value, in both fresh and dried forms, and act as ingredients in a wide variety of prepared foods.

The unique and phenomenal biodiversity of the marine environment provides a large pool of novel and bioactive nutrients for marine organisms. Seaweed is one of the potential sources of these marine bioactive compounds. Seaweed has been consumed in East Asian countries for centuries, and lately, knowledge of the health benefits of dietary seaweed has gained attention in Western cultures [2,3]. According to the Seafood Source report, new products containing seaweed in the European market have increased yearly [2]. Seaweed is rich in non-starch polysaccharides, mainly dietary fibers, and essential minerals such as potassium and calcium [4,5]. The quality of seaweed protein is comparable to other vegetables, mainly due to its high content of essential amino acids. The lipid content of seaweed is generally low, but seaweeds contain high levels of functional omega-3 eicosapentaenoic acid and omega-6 arachidonic acid [5]. Additionally, the value of edible seaweed in human nutrition is strongly recognized for its richness in several phytochemicals. Consequently, seaweed is currently considered a “superfood”, which is a market term recognizing health benefits including superior nutritional profile and richness in bioactive phytochemicals [6].

Primary metabolites of seaweed, such as polysaccharides, proteins, and lipids, are directly involved in their physiological functions under normal growth conditions, while the exposure to different stress conditions, (e.g., ultraviolet radiation, changes in temperature and salinity, or environmental pollutants) stimulates them to produce a wide range of secondary metabolites [6,7]. Among these secondary metabolites, much interest has been paid to seaweed antioxidants [2,6,8-13]. Compared to its terrestrial counterparts, seaweed is potentially a good source of antioxidants and has an advantage over many other organisms in that it can appropriately produce a large amount of desirable and specific bioactive compounds.

Alcoholic extracts from seaweed have been reported to show antioxidant activity due to the presence of polyphenols in the extracts. Red and green seaweeds contain bromophenols, phenolic acids, and flavonoids as the major polyphenols, while phlorotannins are only dominant in brown seaweed [8,14]. Phlorotannins are a group of

complex polymers of phloroglucinol (1,3,5-trihydroxybenzene). Based on the type of structural linkage between the phloroglucinol sub-units, they can be systematically classified into eckols, fucols, fuhalols, ishofuhalols, phloroethols, or fucophloroethols [2]. Many studies have shown that phenolic extracts from seaweeds have several kinds of biological activities [2,6,7,9,15-17]. Although these effects may be due to their ability to modulate oxidative stress and inflammatory cascades, the detailed mechanism remains unclear, mainly due to their complex chemical structure and the difficulty of identifying metabolites and active compounds after absorption.

Carotenoids are also major seaweed antioxidants. They are generally localized in photosynthetic organisms and play an important role in photochemical events [18]. β -Carotene, α -carotene, zeaxanthin, lutein, violaxanthin, neoxanthin, and fucoxanthin (Fx) has been reported in several kinds of seaweed [19]. Among these carotenoids, Fx is a specific carotenoid only found in algae but not terrestrial plants. Fx is photosynthetic pigment mainly found in brown seaweed and Bacillariophyta (diatoms). These algae are widely distributed in cold and temperate ecosystems throughout the world; therefore, Fx is regarded as one of the most abundant carotenoids in nature [20]. In addition to the important role of Fx in the photosynthesis and photoprotection of algae, Fx also has health benefits [21].

This article focuses on the current scientific literature regarding the bioactive significance of Fx, including metabolic, anti-oxidant, anti-obese, anti-diabetic, and anti-cancer activities,.

2. Structure and safety

Fx has a distinctive structure with an allenic bond, a 5,6-monoepoxide, and nine conjugated double bonds (Fig. 1). The conjugated double bond system in the Fx molecule can quench singlet oxygen ($^1\text{O}_2$) and the electron-rich status of Fx makes it more suitable to react with free radicals [21]. Therefore, Fx can protect cells, tissues and other structures against oxidative damage; however, it would be difficult to explain all of its beneficial health effects only by its antioxidant activity [22]. Much attention has been paid to the interaction between Fx or its metabolite and biological key molecules such as receptors and co-activators, where the specific chemical structure of a carotenoid may be essential for binding. To better understand the physiological effect of Fx, more efforts are needed to clarify the ability of Fx or its metabolites in modulating the expression of specific genes and proteins involved in biological systems (Fig. 2).

Fx-rich brown seaweed has been used in Southeast Asian countries as a traditional food. In addition to its use as a food source, the safety of Fx has been demonstrated through animal experiments. A single dose study indicated no mortality and no abnormalities in male and female ICR mice fed 1000 and 2000 mg/kg purified Fx. In a repeated dose study, no adverse effect of purified Fx was observed in mice given 500 and 1000 mg/kg Fx for 30 days [23] and in rats given 200 mg/kg Fx as Fx-containing oil for 13 weeks [24]. Additional animal studies [25-27] and a human study [28] confirmed that Fx caused no toxicities. On the basis of remarkable biological properties and safety, Fx can be considered a nutraceutical ingredient and can be utilized in the food industry and other fields to design new and improved nutraceuticals.

3. Absorption and metabolism

An *In vitro* study showed the hydrolysis of Fx to fucoxanthinol (FxOH) during absorption by Caco-2 cells [29] and the transformation of FxOH into amarouciaxanthin A in human hepatoma HepG2 cells [30] (Fig. 2). An animal study also revealed that dietary Fx is rapidly hydrolyzed to FxOH in the gastrointestinal tract by digestive enzymes, such as lipase and cholesterol esterase within 2 h of administration [30,31]. FxOH was further converted into amarouciaxanthin A through dehydrogenation/isomerization in mice liver microsomes and in HepG2 cells [30,32]. Although FxOH and amarouciaxanthin A have been detected in plasma and all tissues of mice given Fx [30,32-34], most Fx metabolites preferentially accumulate as amarouciaxanthin A in the visceral WAT [33,35]. Yonekura et al. [36] have also reported the preferential accumulation of Fx metabolites in visceral WAT, while these researchers observed that lutein and its metabolites mostly accumulated in the liver. On the other hand, some researchers have demonstrated the absorption of Fx without conversion to any metabolites [33,37].

Several studies have discussed the bioavailability of Fx in cellular, animal, and human models. The absorption rate of Fx in Caco-2 cells was reported to be the lowest out of 11 carotenoids tested [38]; however, the study only analyzed intact Fx but not its metabolites. Based on animal studies showed the ratio of absorbed Fx to the dose calculated using metabolite analysis, FxOH and amarouciaxanthin A exhibited higher levels than astaxanthin [33]. Other animal studies showed that Fx is absorbed in a similar fashion to β -carotene or lutein [30,39,40]. Furthermore, those authors concluded that Fx is more efficiently absorbed than lutein esters. In contrast, Hashimoto et al. [41] demonstrated from a human pharmacokinetics study that the bioaccessibility of Fx

seems to be lower than that of other carotenoids such as β -carotene, lutein or astaxanthin, while they demonstrated that the bioavailability of Fx was higher in human subjects than in mice. To increase bioaccessibility and stability of Fx, many challenges have been done [2]. They include encapsulation of Fx into nanoemulsions, nanoparticles, and other spray-dried powders.

Fx supplementation in a mouse model of obesity effectively decreased excess fat accumulation in abdominal white adipose tissue (WAT). This activity has been reported with at least 60 mg Fx intake/kg mouse/day [35]. On the other hand, a human study demonstrated a significant reduction in the abdominal WAT of obese female volunteers with an intake of Fx less than 0.024 mg/kg/day (2.4 mg intake/day for volunteers with 100 kg average weight) [42]. This difference in the effectiveness between rodents and humans may be due to different absorption rates and/or different sensitivities to Fx. Overall, Fx may be effective even at low levels.

4. Biological activities

4.1. Antioxidant activity

As seen in other carotenoids, Fx can quench singlet oxygen through a physical interaction, where the excess energy of singlet oxygen is transferred to the conjugated polyene structure of Fx [43-45] (Fig. 1). Fx with added energy is excited to a triplet state upon losing energy as heat relaxes to a singlet state without structural changes. The singlet oxygen quenching activity of a carotenoid is generally influenced by the number of conjugated double bonds [45,46]. In addition, the activity is also affected by other factors such as the chain structure and functional groups of carotenoids, solvent viscosity, and substrate dispersion system [47-50]. Sachindra et al. [51] reported that Fx has 9 conjugated double bonds and has a lower quenching ability of singlet oxygen than β -carotene (11 conjugated double bonds), while Hirayama et al. [48] reported little difference in quenching ability between Fx and β -carotene. Further, more effective prevention of lipid hydroperoxide formation by Fx was found in singlet oxygen-mediated plasma lipid oxidation than by β -carotene and α -tocopherol [52].

Another role of Fx as an antioxidant is attributed to the scavenging of a wide range of free radicals (Fig. 1). Fx has a unique chemical structure including an allenic bond, epoxide group, and hydroxyl group. The electron-rich status of Fx makes it more suitable for reactions with the free radicals [21]. Several studies have reported an effective radical scavenging ability of Fx [53]. Although a detailed mechanism has not

yet been determined, Fx can quench different kinds of free radicals such as 1,1-diphenyl-2-picrylhydrazyl (DPPH) [51,54-57], 2,2'-azinobis-3-ethylbenzothiazoline-6-sulphonate (ABTS) [51,57], hydroxyl [51,57], superoxide [51,57], and peroxy [58] radicals.

On the basis of the potential antioxidant properties of Fx, researchers examined the preventive effect of Fx on oxidative damage in biological systems. Murakami et al. [59] screened 19 natural carotenoids for their structure-function relationship with respect to radical scavenging activity. They found that the presence of an allenic bond, as seen in Fx and halocynthiaxanthin, increases the ability to inhibit the formation of superoxide in human promyelocytic HL-60 cells and of nitric oxide in mouse macrophage RAW 264.7 cells. Fx significantly reduced ROS production and the viability of oxidatively damaged monkey kidney fibroblast cells [60], human HaCaT keratinocytes [61], human hematoma HepG2 cells [62], and normal human hepatic L02 cells [63]. The antioxidant activity of Fx has also been reported *in vivo*. When oxidative stress was induced by retinol deficiency in rats, Fx significantly reduced lipid hydroperoxide levels of plasma, liver, and liver microsomes [64]. In another animal experiment [65], Fx supplementation significantly increased the total antioxidant capacity in plasma. The antioxidant activity of Fx is not only based on its singlet oxygen and free radical scavenging activities but also strongly related to its upregulation of antioxidant enzymes such as catalase [64] and glutathione peroxidase [65]. In the upregulation pathway, several studies have demonstrated the involvement of the activation of Akt/nuclear factor-erythroid 2-related (Nrf2) by Fx [63,65,66].

4.2. Anti-obesity effect

Many reviews have been published on the protective effects of Fx against various diseases [7,21,53,67-76] (Fig. 2). Of all characteristics of Fx, anti-obesity is certainly the most well-studied and promising [21,67,68,70,72,76].

Anti-obesity properties of Fx were first discovered in rats and mice given brown seaweed lipids containing Fx [77]. This effect has been confirmed using various animal models [78-84]. In addition, a comparative study indicated that Fx attenuates excess fat accumulation in the abdominal WAT of the obese KK-*A^y* mice [79] and of C57BL/6J mice fed a high-fat diet [83], while no effect was found in the C57BL/6J mice fed a normal-fat diet [79]. These results suggest the suppressive effect of Fx on WAT weight gain is specific for adiposity in the development of obesity in mice. This specificity will be important for the safe application of Fx in human therapies for obesity. In a human

clinical trial, 2.4 mg Fx daily for volunteers (average weight 100 kg) resulted in a significant decrease in body fat, body weight, liver fat content, and serum triglyceride levels, which was accompanied by improvement in liver function tests [42]. The clinical trial also demonstrated an increase in the resting energy expenditure after >2.4 mg Fx intake. Hitoie and Shimoda [28] also examined the effect of Fx on mildly obese Japanese volunteers and reported a significant reduction of relative body weight, body mass index, and visceral fat area after 3 mg daily Fx intake for 4 weeks. Relative values of total fat mass, subcutaneous fat area, waist circumference, and right thigh circumference were also significantly lower after 1 mg Fx intake compared to the placebo group. Another study reported the induction of BAT expression by Fx intake in obese human subjects assessed by ¹⁸F-fluorodeoxyglucose-positron emission tomography [85].

Obesity is defined as a condition of excess body fat induced by increased energy intake and/or reduced energy expenditure. Obesity is associated with a large number of metabolic disorders that induce cardiovascular and various other non-communicable diseases. Lifestyle interventions, such as a change in dietary habits and increased physical activity, are fundamentally important to obesity therapy [86]. In addition to these essential interventions, much attention has been paid to nutritional and dietary factors, especially metabolically active food compounds. Major molecular mechanisms for controlling obesity with nutrition include reducing food intake through the control of signals from the gut and adipose tissue; inhibiting nutrient absorption; increasing thermogenesis to dissipate food energy as heat; and modulating fat synthesis/lipolysis or adipose differentiation/apoptosis [87,88]. Many functional food components have been shown to alter energy metabolism by influencing fat absorption, substrate utilization rate, and thermogenesis.

Upregulation of sympathetically mediated thermogenesis is the most targeted component when developing functional foods for obesity therapy. Uncoupling protein 1 (UCP1) expression is a major factor in this thermogenic process. UCP1 can be induced in brown adipose tissue (BAT) [89-91] and in beige adipocytes of WAT [92-94]. Although several mechanisms have been proposed for the anti-obesity effects of Fx, adaptive thermogenesis via UCP1 induction in adipose tissue is the major target of Fx [21,22,53,68,72,73,95] (Fig. 3). Activated UCP1, short circuits the electrochemical gradient normally used to drive adenosine triphosphate (ATP) synthesis. This can occur with the re-entry of protons into the mitochondrial matrix, bypassing ATP synthase. The uncoupling of oxidative phosphorylation releases excess energy intake as heat. Feeding Fx to mice increased BAT weight and induced UCP1 mRNA and protein expressions in abdominal WAT [77,81,82], suggesting that the anti-obesity effect of Fx is derived from

an increase in the adaptive thermogenesis through UCP1 expression. In addition, Fx supplementation in animal models increased the mRNA and protein expression of several biomolecules, such as β 3-adrenarine receptor (β 3Ad) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC-1), in WAT [83,96]. The upregulation of β 3Ad and PGC-1 are known to positively regulate UCP-1 expression [21]. Furthermore, PGC-1 upregulation can also induce mitochondrial biogenesis. Therefore, the anti-obesity effect of Fx would also be related to the increase in metabolic rate induced by mitochondrial activation [97] (Fig. 3).

Several studies have also shown that Fx ameliorates obesity through its effects on lipid metabolism. Woo et al. [98] reported an increase in the content of non-digested fecal lipids and a decrease in hepatic lipid and plasma triacylglycerol levels by Fx supplementation to C57BL/6N mice fed a high-fat diet. The effect of Fx could be explained by reduced activity of hepatic lipogenesis and enhanced activity of fatty acid β -oxidation [98,99]. In another study using obese mice fed a high fat diet [84], the mRNA expression and activity of lipogenic enzymes were significantly downregulated in a dose-dependent manner in epididymal adipose tissue, with simultaneous upregulation of fatty acid β -oxidation. In addition, Fx increased the activities of key enzymes in lipid metabolism, such as AMP-activated protein kinase and its downstream target acetyl-CoA carboxylase in epididymal adipose tissue of diet-induced obese mice [80]. Moreover, Fx and FxOH have been demonstrated to inhibit pancreatic lipase activity and suppress triacylglycerol absorption after oral infusion with oil [31]. Improvement of hepatic lipid metabolism by Fx intake would be related to risk reduction in non-alcoholic fatty liver disease (NAFLD) [100]. Potential protective functions of Fx against the development of NAFLD have also been recognized in a human study [42]. Consumption of an Fx supplement containing 2.4 mg of pure Fx for 16 weeks decreased liver fat content and serum concentrations of TAG and C-reactive protein in obese premenopausal women with NAFLD.

The regulatory effect of Fx and Fx metabolites on adipocyte differentiation may be involved in its anti-obesity effects [21,73]. These compounds suppressed murine pre-adipocyte differentiation to mature adipocytes by inhibiting intracellular lipid accumulation and decreasing glycerol-3-phosphate dehydrogenase activity [101,102]. When the suppressive effect of Fx and Fx metabolites on the differentiation of 3T3-L1 preadipocytes to adipocytes was compared [101,102], amarouciaxanthin A showed the strongest effect, followed by FxOH and Fx. Fx and FxOH downregulated adipogenic genes, such as peroxisome proliferator-activated receptor γ (PPAR γ) and CCAAT/enhancer binding protein α (C/EBP α), in a dose-dependent manner. On the

other hand, Kang et al. [103] has demonstrated that the effect of Fx on adipocytes depends on its differentiation stage, early (days 0-2), intermediate (days 2-4), and late stage (days 4-7). Fx paradoxically promoted adipocyte differentiation during the first two days by increasing the expression of PPAR γ , C/EBP α , sterol regulatory element-binding protein 1c, and adipocyte fatty acid-binding protein, while it inhibited differentiation at later stages by reducing these protein expression levels.

Okada et al. [104] compared the suppressive effect of 13 naturally occurring carotenoids on the differentiation of 3T3-L1 adipose cells. Among these carotenoids, neoxanthin did show suppressive effects on lipid accumulation, glycerol-3-phosphate dehydrogenase (GPDH) activity and adipocyte protein 2 expression in the 3T3-L1 differentiation. However, treatment with (rac)- α -carotene, carotenoids with keto group (citranaxanthin, rhodoxanthin, canthaxanthin) and an epoxy group (β -carotene 5,6-epoxide) did not result in apparent changes in the level of GPDH activity. The same was true for hydroxyl carotenoid (β -cryptoxanthin, lutein), epoxy-hydroxy carotenoids (violaxanthin, antheraxanthin, lutein epoxide), and keto-hydroxy carotenoids (capsorubin). Interestingly, neoxanthin contain allenic bond, a 5,6-monoepoxide, and three hydroxyl groups and this structure is very similar in structure to FxOH and amarousiaxanthin A, major metabolites of Fx. These findings provide further evidence for the theory that suppressive effect on adipocyte differentiation in carotenoids are related to structural properties, where allenic bond is essential for the expression of the activity.

4.3. Anti-diabetic effect

Obesity has been recognized as a driver of type 2 diabetes [105]. Indeed, the majority of patients with type 2 diabetes are obese [106], and the increased incidence of type 2 diabetes has paralleled that of obesity. Excess fat accumulation in abdominal WAT in obese individuals increases the secretion of biologically active mediators, termed adipokines/chemokines, from adipocytes, as part of the endocrine system [21]. Development of obesity leads to an increase in pro-inflammatory adipokines such as tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6) and monocyte chemoattractant protein-1. These pro-inflammatory adipokines induce macrophage infiltration into the abdominal WAT, leading to chronic low-grade inflammation. Furthermore, saturated fatty acid and TNF- α derived from adipocytes and macrophages, respectively, initiate a paracrine loop that leads to inflammation in the adipose tissue and upregulation of pro-inflammatory adipokine secretions. These adipokines are reported to increase

insulin sensitivity [107]. On the other hand, Fx supplementation significantly inhibited macrophage infiltration and downregulated pro-inflammatory adipokine expression and secretion in the abdominal WAT of obese/diabetes KK-*A^y* mice, resulting in the improvement of insulin resistance and subsequent blood glucose levels [79,82]. Normalization of blood glucose levels by Fx intake has also been observed in C57BL/6J mice fed a high fat diet [83,98,99], while Fx did not affect the blood glucose levels in C57BL/6J mice fed a normal diet [79], suggesting the specificity of the lowering effect of Fx on diabetes.

Another possible mechanism for the anti-diabetic effect of Fx is the regulation of glucose transporter 4 (GLUT4) [83,96]. GLUT4 protein is the predominant isoform of the glucose transporters expressed abundantly in skeletal muscle and adipose tissue. With insulin and other stimuli, GLUT4 expression is upregulated, quickly moves to the plasma membrane from an intracellular location, and promotes glucose uptake [108]. However, in type 2 diabetes mellitus, insulin signaling is impaired and GLUT4 expression and its translocation is attenuated [109]. When mice were fed high fat (HF) or normal fat (NF) diets, the HF group experienced hyperglycemia, hyperinsulinemia and hyperleptinemia with a significant decrease in GLUT4 mRNA levels in skeletal muscle compared to the NF group [83]. These disorders were completely normalized by the addition of Fx to the HF diet, and GLUT4 mRNA levels in the HF group with Fx were restored to levels observed in the NF group. These anti-diabetic effects of Fx were recapitulated in obese/diabetes KK-*A^y* mice [96]. A significant increase in GLUT4 levels was found in the extensor digitorum longus muscle of the obese/diabetes mouse model together with an upregulation of PGC-1 α expression [96]. PGC-1 α is an important co-activator that has been implicated in the regulation of mitochondrial biogenesis and the activation of GLUT4 [110,111]. In addition, Fx supplementation significantly increased GLUT4 translocation to plasma membranes from the cytosol in the soleus muscle of KK-*Ay* mice.

4.4. Anticancer activity

Compared with other carotinoids, Fx is known to exhibit stronger anti-proliferative effects on several cancer cell types [69,112]. Fx strongly decreased the viability of many cancer cell types such as human neuroblastoma GOTT [113], leukemia (HD-60) [114], epithelial colorectal adenocarcinoma (Caco-2, DLD-1 and HT-29) [115], human prostate cancer (PC-3) [116], mouse melanoma (B16) and human colorectal carcinoma (HCT116) [117], while it did not affect the normal cell viability [117]. Kotake-Nara et

al. [118] compared the effect of 15 kinds of carotenoids (phytoene, phytofluene, ξ -carotene, lycopene, α -carotene, β -carotene, β -cryptoxanthin, canthaxanthin, astaxanthin, capsanthin, lutein, zeaxanthin, vioxanthin, neoxanthin, and fucoxanthin) present in foodstuffs on the growth of human prostate cancer cell lines (PC-3, DU 145 and LNCap). Among the carotenoids evaluated, allenic carotenoids, neoxanthin and Fx, showed the higher activity in the growth reduction of these prostate cancer cells as compared with other kinds of carotenoids without allenic bond, suggesting the importance of allenic bond in the anti-proliferative ability of carotenoids.

Fx intake also suppressed the number and growth of tumors in animal models [119-122]. In addition, brown seaweed extract (containing Fx showed chemopreventive activity against the formation of aberrant crypt foci, a preneoplastic marker for colon cancer, in rats [123,124]. To investigate the underlying mechanisms of the anti-cancer potential of Fx, many studies have focused on several biomolecules and signaling pathways involved in either cell cycle arrest, apoptosis, or metastasis suppression [37,67,69,71,112]. These studies suggest that Fx could arrest the cell cycle of tumor cells in the G0/G1 and/or G2/M phase by altering the expression of various genes including upregulating GADD45, p21 and p27 and downregulating cyclin D1, cyclin D2, CDK4, and survivin [37,67,69,71,75,112,125]. The apoptotic effect of Fx is well-studied because apoptosis of cancer cells is a promising method to control and treat cancer. Fx induces apoptosis by targeting different molecular pathways including Bcl-2, caspase, mitogen-activated protein kinase, nuclear factor kappa B families, and others [69,71,75].

Recently, efforts have focused on the chemopreventive effect of Fx in colorectal cancer. Takahashi et al. [126] found that FxOH showed higher anti-proliferative activity than Fx on different kinds of colorectal cancer cell lines including DLD-1, HCT116, SW620, Caco-2, Colo205, and WiDr. The anti-proliferative capacity of FxOH was also effective in colorectal cancer stem cells (CD44^{high} and EpCAM^{high} cells) [127]. These cells initiate colorectal carcinogenesis and play a central role in tumor development, exhibiting several biological properties including self-renewal, multipotential, drug-resistance, sphere formation, and tumor formation in xenograft models. FxOH significantly inhibited the growth of the colorectal cancer stem cells [127]. Fx also suppressed sphere-forming activity, migration and invasion of colorectal cancer stem cells in a dose-dependent manner [128] and downregulated several biomolecules related to cell proliferation, cell cycle, metastasis, and extracellular adhesion [127]. In addition, Fx induced anchorage-dependent apoptosis in human colorectal cancer (CRC) cells through the suppression of integrin signals [129,130]. In animal models, Fx

administration significantly suppressed tumor development in a xenograft model of colorectal cancer [127,131], decreased the number of colorectal polyps, and decreased colonic lesions compared to untreated control mice [132]. In addition, Fx administration resulted in significantly lower numbers of colorectal cancer stem cell-like cells, cancer-associated fibroblast-like, tumor-associated macrophage-like and dendritic cell-like cells in colonic mucosa compared to untreated control mice [132].

4.5. Other activities

Given that metabolic syndrome and obesity are regarded as major risk factors for the induction of cardiovascular disease (CVD), much attention has been paid to the anti-obesity and anti-diabetic effects Fx. In addition, Fx is known to show *in vivo* anti-oxidant, anti-inflammatory, and anti-hypertensive activities. These abilities are also important in the context of CVD. The antioxidant activity of Fx has been well-described, and several studies have reported anti-inflammatory [7] and anti-hypertensive [53,133] activities of Fx. Effective downregulation of lipopolysaccharide-induced inflammatory signaling pathways has been found in cellular models supplemented with Fx [134-136]. In these models, Fx significantly suppressed the expression and secretion of inflammatory mediators such as nitric oxide, prostaglandin E₂, TNF- α , IL-6, and IL-1 β and inflammatory cytokines such as cyclooxygenase (COX) and inducible nitric oxide synthase (iNOS) [137]. The levels of inflammatory markers such as IL-1 β , TNF- α , iNOS, and COX-2 were downregulated in an obese mouse model [138]. The protective effect of fucoxanthin was further described in UV-induced inflammation in cellular [139] and animal [140] models. Fx has also been reported exhibit anti-hypertensive properties. Supplementation of brown seaweed containing Fx delayed the incidence of stroke symptoms and increased the life span of stroke-prone spontaneously hypertensive rats [141], although there was no significant difference in the blood pressure with Fx intake. Fx isolated from brown seaweed may also have a preventive effect on ischemic cultured neuronal cell death. An interesting, extra metabolic effect of Fx is the promotion of the synthesis of docosahexaenoic acid (DHA) in the liver, resulting in improvements in the lipid profile [34,142]. DHA is known to positively influence human nutrition and health including cardioprotection. DHA could inhibit the development of inflammation in endothelial cells, alter the function and regulation of vascular biomarkers, and reduce cardiovascular risk [143]. It can also improve hypertriglyceridemia, which is known to increase cardiovascular risk [144]. Therefore, the protective effect of Fx on CVD maybe explained by an increase in DHA levels.

Fucoxanthin protected neuronal cells against oxidative damage induced by H₂O₂ [145,146] and oligomers of β -amyloid (A β) [147,148]. This effect involved the activation of PI3-K/Akt cascade and inhibition of ERK pathway by Fx [146,148]. A β oligomers are known as major neurotoxins in Alzheimer's disease (AD). Fx potently reduced the formation of A β oligomers *in vitro* and *in vivo* [149]. In the brains of AD patients, neuronal degeneration is accompanied by markers of microglial activation and inflammation, as well as oxidant damage. Fx can ameliorate oxidative stress and inflammation in A β 42-induced BV2 microglia cells [150]. In addition, Fx plays a protective role in animal models of traumatic brain injury [151] and middle cerebral artery occlusion [152]. Although the underlying mechanism of the neuroprotective effect of Fx has not been fully elucidated, molecular docking studies suggest the importance of interactions between Fx and key proteins related to brain function [153]. Paudel et al. [154] have shown that Fx could serve as a potent dopamine D3/D4 agonist that might be useful in the management of neurodegenerative diseases, especially Parkinson's disease. On the other hand, β -site amyloid precursor protein cleaving enzyme 1 (BACE1) levels are known to be elevated in sporadic AD brains at disease onset. The BACE1 levels are upregulated under stress conditions such as cerebral ischemia, hypoxia, and oxidative stress. Fx inhibited the BACE1 activity through the interaction between two hydroxyl groups on the Fx molecule and two additional BACE1 residues (Gly11 and Ala127) [155].

5. Fx source and its extraction

Although Fx can be synthesized chemically, extraction from brown seaweed is a more accessible, safe, and economic method [75]. The Fx content in brown seaweed varies greatly by species, geographical location, season, temperature, salinity, and light intensity, as well as interactions among these factors [5]. Comparative studies on 15 brown seaweed samples collected near the northern coast of Japan have revealed that higher levels of Fx were found in *Sargassum horneri* (Turner) (370 mg/100 g dry weight) and *Cystoseira hakodatensis* (Yendo) (240 mg/100 g dry weight) [156]. The same research group also examined seasonal changes in the lipid components of the two brown seaweeds, *S. horneri* and *C. hakodatensis* [157]. They collected young thalli of both brown seaweeds cultivated in the northern coast of Japan. The Fx content of both brown seaweeds increased from October/November, reached a maximum in January, and decreased thereafter. In January, the Fx content of *S. horneri* and *C. hakodatensis* was 449 mg and 363 mg/100 g dry weight, respectively. Furthermore, by controlling the

cultivation conditions, such as temperature, light, and depth, a high content of Fx (1080 mg/100 g dry weight) was found in *S. horneri* cultivated in cold water [158].

Fx is generally extracted from brown seaweed with organic solvents [159-166]. However, recovery remains low due to the presence of various physical and chemical barriers in the complex matrix. In addition, conventional extraction methods are time-consuming and require a large amount of organic solvent. To overcome the disadvantages of conventional solvent extractions, several studies have reported advanced techniques, such as pressurized liquid extraction [167], enzyme-assisted extraction [168], and extraction with supercritical CO₂ [169-173]. Much interest has been generated in the development of new, eco-friendly alternatives to petrochemical organic solvents. These ideal alternative “green” solvents, should be nontoxic, bio-based, and environmentally friendly. Supercritical CO₂ is regarded as a green solvent. However, this method requires expensive investment and a complex operating system with high operating costs [174-176]. In addition, the solubility of Fx in supercritical CO₂ is low, requiring the use of cosolvents [172].

Considering the increase in consumer concern regarding organic solvent contamination in the final food product, the development of new eco-friendly solvents is still required. The use of edible oils for the extraction of Fx from brown seaweed is promising. Edible oils are regarded as green alternative solvents with no volatile organic compounds, low toxicity for humans, and a limited impact on the environment. Due to their oil solubility, carotenoids can be extracted with edible oils from natural resources. Products from carotenoid extraction with edible oils can be directly used as food materials without purification, and the oil protects carotenoids from degrading [177]. This advantage is not found using other green extraction methods. When the edible oil used for carotenoid extraction shows any type of nutritional functionality, as seen in omega-3 oils [178,179], medium-chain triacylglycerol (TAG) (MCT) [180-182], olive oil [183,184], and others, the extracts are expected to show the combined biological activities originating from phytochemicals such as carotenoids and from the functional oils.

Although several studies have highlighted many advantages for extracting carotenoids with edible oils from shrimp waste [185-188], crawfish waste [189-191], microalgae, *Haematococcus pluvialis* [192,193], and fresh carrots [194], little is known about their application to Fx extraction. Recently, Teramukai et al. [195] reported effective extraction of Fx from brown seaweed, *Sargassum horneri*. When the extraction rate was compared with 12 types of edible oils, more Fx could be extracted with short-chain (tributylin, C4 and tricaprionin, C6) TAG, medium-chain (tricaprylin,

C8) TAG (MCT), and fish oil compared with other edible oils; e.g., rice bran, rice germ, rapeseed, sesame, corn, soybean, and linseed [195]. MCT reportedly increases the anti-obesity effect of Fx [81]. WAT weight gain was markedly lower in diabetic/obese KK-*A*^y mice fed a mixture of Fx (0.1%) and MCT (0.9%) than in mice fed Fx (0.1%) alone. In addition, the expression of UCP1 was also markedly increased by MCT co-supplementation with Fx. Furthermore, an increase in anti-obesity and anti-diabetic effects of Fx has been reported with the combination of fish oil rich in EPA and DHA [82]. These results suggest that Fx extracts from brown seaweed with MCT and fish oil may show higher biological activities than those with organic solvent.

6. Conclusion

Since the discovery of the anti-obesity effect of Fx with UCP1 induction in abdominal WAT, many studies have been conducted on the nutritional impact of Fx. Increasing data clearly shows that Fx is effective at reducing the risk of a surprisingly wide variety of dysfunctions and diseases, including metabolic syndrome, obesity, heart disease, diabetes, cancer, hypertension, and reactive oxygen species- and inflammation-associated disorders. To explain the underlying mechanism, studies have demonstrated the modulation effect of Fx or its metabolites on signaling pathways related to these dysfunctions and diseases. The biological activities of Fx may be due to its unique chemical structure and its interaction with important biomolecules such as receptor proteins. Thus, more research is required to clarify the interactions by analyzing binding sites of the Fx molecule, the affinity for specific biomolecules, the molecular docking, etc.

References

- [1] J.M. Lorenzo, R. Agregán, P.E.S. Munekata, D. Franco, J. Carballo, S. Sahin, R. Lacomba, F.J. Barba, Proximate composition and nutritional value of three macroalgae: *Ascophyllum nodosum*, *Fucus vesiculosus* and *Bifurcaria bifurcata*. Mar. Drugs 15 (2017) 360 <https://doi.org/10.3390/md15110360>.
- [2] N.C. Afonso, M.D. Catarino, A.M.S. Silva, S.M. Cardoso, Brown macroalgae as valuable food ingredients, Antioxidants 8 (2019) 365 <https://doi.org/10.3390/antiox8090365>.
- [3] A. Lopez-Santamarina, J.M. Miranda., A. del Carmen Mondragon, A. Lamas, A. Cardelle-Cobas, C.M. Franco, A. Cepeda, Potential use of marine seaweeds as

- prebiotics: A review, *Molecules* 25 (2020) 1004
<https://doi.org/10.3390/molecules25041004>.
- [4] A.R. Circuncisão, M.D. Catarino, S.M. Cardoso, A.M.S. Silva, Minerals from macroalgae origin: Health benefits and risks for consumers, *Mar. Drugs* 16 (2018) 400 <https://doi.org/10.3390/md16110400>.
- [5] K. Miyashita, N. Mikamia, M. Hosokawa, Chemical and nutritional characteristics of brown seaweed lipids: A review. *J. Functional Foods* 5 (2013) 1507-151 <https://doi.org/10.1016/j.jff.2013.09.019>.
- [6] G. Lopes, P.B. Andrade, P. Valentão, Phlorotannins: towards new pharmacological interventions for diabetes mellitus type 2, *Molecules* 22 (2017) E56 <https://doi.org/10.3390/molecules22010056>.
- [7] G.P. Rosa, W.R. Tavares, P.M.C. Sousa, A.K. Pagès, A.M.L. Seca, D.C.G.A. Pinto, Seaweed secondary metabolites with beneficial health effects: An overview of successes in in vivo studies and clinical trials, *Mar. Drugs* 18 (2019) E8 <https://doi.org/10.3390/md18010008>.
- [8] P. Cherry, S. Yadav, C.R. Strain, P.J. Allsopp, E.M. McSorley, R.P. Ross, C. Stanton, Prebiotics from seaweeds: An ocean of opportunity? *Mar. Drugs* 17 (2019) 327 <https://doi.org/10.3390/md17060327>.
- [9] M. Gómez-Guzmán, A. Rodríguez-Nogales, F. Algieri, J. Gálvez, Potential role of seaweed polyphenols in cardiovascular-associated disorders, *Mar. Drugs* 16 (2018) 250 <https://doi.org/10.3390/md16080250>.
- [10] D.H.A. Rocha, A.M.L. Seca, D.C.G.A. Pinto, Seaweed secondary metabolites in vitro and in vivo anticancer activity, *Mar. Drugs* 16 (2018) 410 <https://doi.org/10.3390/md16110410>.
- [11] B. Salehi, J. Sharifi-Rad, A.M.L. Seca, D.C.G.A. Pinto, I. Michalak, A. Trincone, A.P. Mishra, M. Nigam, W. Zam, N. Martins, Current trends on seaweeds: Looking at chemical composition, phytopharmacology, and cosmetic applications, *Molecules* 24 (2019) 4182 <https://doi.org/10.3390/molecules24224182>.
- [12] K.K.A. Sanjeewa, E.-A. Kim, K.-Tae Son, Y.Jin Jeon, Bioactive properties and potentials cosmeceutical applications of phlorotannins isolated from brown seaweeds: A review, *J. Photoch. Photobio. B* 162 (2016) 100-105 <https://doi.org/10.1016/j.jphotobiol.2016.06.027>.
- [13] T. Shin, M. Ahn, J.W. Hyun, S.H. Kim, C. Moon, Antioxidant marine algae phlorotannins and radioprotection: A review of experimental evidence, *Acta Histochem.* 116 (2014) 669-674 <https://doi.org/10.1016/j.acthis.2014.03.008>.
- [14] A.-M. Cikoš, S. Jokić, D. Šubarić, I. Jerković, Overview on the application of

- modern methods for the extraction of bioactive compounds from marine macroalgae, *Mar. Drugs* 16 (2018) 348 <https://doi.org/10.3390/md16100348>.
- [15] M.C. Barbalace, M. Malaguti, L. Giusti, A. Lucacchini, S. Hrelia, C. Angeloni, Anti-inflammatory activities of marine algae in neurodegenerative diseases, *Int. J. Mol. Sci.* 20 (2019) 3061 <https://doi.org/10.3390/ijms20123061>.
- [16] N. Besednova, T. Zaporozhets, T. Kuznetsova, I. Makarenkova, L. Fedyanina, S. Kryzhanovsky, O. Malyarenko, S. Ermakova, Metabolites of seaweeds as potential agents for the prevention and therapy of influenza infection, *Mar. Drugs* 17 (2019) 373 <https://doi.org/10.3390/md17060373>.
- [17] I. Wijesekara, N.Y. Yoon, S.-K. Kim, Phlorotannins from *Ecklonia cava* (Phaeophyceae): Biological activities and potential health benefits, *Biofactors* 36 (2010) 408-414 <https://doi.org/10.1002/biof.114>.
- [18] T. Polívka, H.A. Frank, Molecular factors controlling photosynthetic light harvesting by carotenoids, *Acc. Chem. Res.* 43 (2010) 1125-1134 <https://doi.org/10.1021/ar100030m>.
- [19] E. Susanto, A.S. Fahmi, M. Hosokawa, K. Miyashita, Variation in lipid components from 15 species of tropical and temperate seaweeds. *Mar. Drugs* 17 (2019) E630 <https://doi.org/10.3390/md17110630>.
- [20] T. Matsuno, Aquatic animal carotenoids, *Fisheries Sci.* 67 (2001) 771-783 <https://doi.org/10.1046/j.1444-2906.2001.00323.x>.
- [21] K. Miyashita, M. Hosokawa, Fucoxanthin in the management of obesity and its related disorders, *J. Functional Foods* 36 (2017) 195-202 <https://doi.org/10.1016/j.jff.2017.07.009>.
- [22] K. Miyashita, S. Nishikawa, F. Beppu, T. Tsukui, M. Abe, M. Hosokawa, Allenic carotenoid, fucoxanthin, as a novel marine nutraceutical from brown seaweed, *J. Sci. Food Agric.* 91 (2011) 1166-1174 <https://doi.org/10.1002/jsfa.4353>.
- [23] F. Beppu, Y. Niwano, T. Tsukui, M. Hosokawa, K. Miyashita, Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice, *J. Toxicol. Sci.* 34 (2009) 501-510 <https://doi.org/10.2131/jts.34.501>.
- [24] K. Iio, Y. Okada, M. Ishikura, Single and 13-week oral toxicity study of fucoxanthin oil from microalgae in rats, *Shokuhin Eiseigaku Zasshi* 52 (2011) 183-189 <https://doi.org/10.3358/shokueishi.52.183>.
- [25] K. Iio, Y. Okada, M. Ishikura, Bacterial reverse mutation test and micronucleus test of fucoxanthin oil from microalgae, *Shokuhin Eiseigaku Zasshi* 52 (2011) 190-193 <https://doi.org/10.3358/shokueishi.52.190>.
- [26] T. Kadekaru, H. Toyama, T. Yasumoto, 2008. Safety evaluation of fucoxanthin

- purified from *Undaria pinnatifida*. *Nippon Shokuhin Kagaku Kogaku Kaishi*, 55 (2008) 304-308 <https://doi.org/10.3358/shokueishi.52.190>.
- [27] F. Beppu, Y. Niwano, E. Sato, M. Kohno, T. Tsukui, M. Hosokawa, K. Miyashita, *In vitro* and *in vivo* evaluation of mutagenicity of fucoxanthin (FX), and its metabolite fucoxanthinol (FXOH), *J. Toxicol. Sci.* 34 (2009) 693-698 <https://doi.org/10.2131/jts.34.693>.
- [28] S. Hito, H. Shimoda, H., Seaweed fucoxanthin supplementation improves obesity parameters in mildly obese Japanese subjects, *Functional Foods Health Dis.* 7 (2017) 246-262 <https://doi.org/10.31989/ffhd.v7i4.333>.
- [29] T. Tsu, V. Baskaran, W. Tsuzuki, A. Nagao, Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice, *J. Nutr.* 132 (2002) 946-951 <https://doi.org/10.1093/jn/132.5.946>.
- [30] A. Asai, T. Sugawara, H. Ono, A. Nagao, Biotransformation of fucoxanthinol into amarouciaxanthin a in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites, *Drug Metab. Dispos.* 32 (2004) 205-211 <https://doi.org/10.1124/dmd.32.2.205>.
- [31] M. Matsumoto, M. Hosokawa, N. Matsukawa, M. Hagio, A. Shinoki, M. Nishimukai, K. Miyashita, T. Yajima, H. Hara, Suppressive effects of the marine carotenoids, fucoxanthin and fucoxanthinol on triglyceride absorption in lymph duct-cannulated rats, *Eur. J. Nutr.* 49 (2010) 243-249 <https://doi.org/10.1007/s00394-009-0078-y>.
- [32] T. Sugawara, V. Baskaran, W. Tsuzuki, A. Nagao, Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice, *J. Nutr.*, 132 (2002) 946-951 <https://doi.org/10.1093/jn/132.5.946>.
- [33] T. Hashimoto, Y. Ozaki, M. Taminato, S.K. Das, M. Mizuno, K. Yoshimura, T. Maoka, K. Kanazawa, The distribution and accumulation of fucoxanthin and its metabolites after oral administration in mice, *Br. J. Nutr.* 102 (2009) 242-248 <https://doi.org/10.1017/S0007114508199007>.
- [34] T. Tsukui, T. Baba, M. Hosokawa, T. Sashima, K. Miyashita, Enhancement of hepatic docosahexaenoic acid and arachidonic acid contents in C57BL/6J mice by dietary fucoxanthin, *Fisheries Sci.* 75 (2009) 261-263 <https://doi.org/10.1007/s12562-008-0018-4>.
- [35] M.K.W.A. Airanthi, N. Sasaki, S. Iwasaki, N. Baba, M. Abe, M. Hosokawa, K. Miyashita, Effect of brown seaweed lipids on fatty acid composition and lipid hydroperoxide levels of mouse liver, *J. Agric. Food Chem.* 59 (2011) 4156-4163 <https://doi.org/10.1021/jf104643b>.

- [36] L. Yonekura, M. Kobayashi, M. Terasaki, A. Nagao, Keto-carotenoids are the major metabolites of dietary lutein and fucoxanthin in mouse tissues, *J. Nutr.* 140 (2010) 1824-1831 <https://doi.org/10.3945/jn.110.126466>.
- [37] Y.P. Zhang, H. Wu, H.M. Wen, H. Fang, Z. Hong, R.Z. Yi, R. Liu, Simultaneous determination of fucoxanthin and its deacetylated metabolite fucoxanthinol in rat plasma by liquid chromatography-tandem mass spectrometry, *Mar. Drugs* 13 (2015) 6521-6536 <https://doi.org/10.3390/md13106521>.
- [38] T. Tsuzuki, M. Kushiro, H. Zhang, E. Nara, H. Ono, A. Nagao, Lysophosphatidylcholine enhances carotenoid uptake from mixed micelles by Caco-2 human intestinal cells, *J. Nutr.* 131 (2001) 2921-2927 <https://doi.org/10.1093/jn/131.11.2921>.
- [39] V. Baskaran, T. Tsu, A. Nagao, Phospholipids affect the intestinal absorption of carotenoids in mice, *Lipids* 38 (2003) 705-711 <https://doi.org/10.1007/s11745-003-1118-5>.
- [40] E. Kotake-Nara, A. Nagao, Absorption and metabolism of xanthophylls, *Mar. Drugs* 9 (2011) 1024-1037 <https://doi.org/10.3390/md9061024>.
- [41] T. Hashimoto, Y. Ozaki, M. Mizuno, M. Yoshida, Y. Nishitani, T. Azuma, A. Komoto, T. Maoka, Y. Tanino, K. Kanazawa, Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract, *Br. J. Nutr.* 107 (2012) 1566-1569 <https://doi.org/10.1017/S0007114511004879>.
- [42] M. Abidov, Z. Ramazanov, R. Seifulla, S. Grachev, The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat, *Diab. Obes. Met.* 12 (2010) 72-81 <https://doi.org/10.1111/j.1463-1326.2009.01132.x>.
- [43] F. Böhm, R. Edge, G. Truscott, Interactions of dietary carotenoids with activated (singlet) oxygen and free radicals: potential effects for human health. *Mol. Nutr. Food Res.* 56 (2012) 205-216 <https://doi.org/10.1002/mnfr.201100222>.
- [44] K.K. Namitha, P.S. Negi, Chemistry and biotechnology of carotenoids. *Crit. Rev. Food Sci. Nutr.* 50 (2010) 728-760 <https://doi.org/10.1080/10408398.2010.499811>.
- [45] W. Stahl, H. Sies, Antioxidant activity of carotenoids, *Mol. Aspects Med.* 24 (2003) 345-351 [https://doi.org/10.1016/S0098-2997\(03\)00030-X](https://doi.org/10.1016/S0098-2997(03)00030-X).
- [46] A. Cantrell, D. J. McGarvey, T.G. Truscott, F. Rancan, F. Bohm, Singlet oxygen quenching by dietary carotenoids in a model membrane environment, *Arch. Biochem. Biophys.* 412 (2003) 47-54 [https://doi.org/10.1016/s0003-9861\(03\)00014-6](https://doi.org/10.1016/s0003-9861(03)00014-6).

- [47] P.F. Conn, W. Schalch, G.T. Truscott, The singlet oxygen and carotenoid interaction, *J. Photoch. Photobio. B* 11 (1991) 41-47
[https://doi.org/10.1016/1011-1344\(91\)80266-K](https://doi.org/10.1016/1011-1344(91)80266-K).
- [48] O. Hirayama, K. Nakamura, S. Hamada, Y. Kobayashi, Y., Singlet oxygen quenching ability of naturally occurring carotenoids, *Lipids* 29 (1994) 149-150
<https://doi.org/10.1007/BF02537155>.
- [49] P.D. Mascio, M.E. Murhy, H. Sies, Antioxidant defense systems: the role of carotenoids, tocopherols, and thiols, *Am. J. Clin. Nutr.* 53 (1991) 194S-200S
<https://doi.org/10.1093/ajcn/53.1.194S>.
- [50] G. Sandmann, Antioxidant protection from UV- and light-stress related to carotenoid structures, *Antioxidants (Basel)* 8 (2019) E219
<https://doi.org/10.3390/antiox8070219>.
- [51] N.M. Sachindra, E. Sato, H. Maeda, M. Hosokawa, Y. Niwano, M. Kohno, K. Miyashita, Radical scavenging and singlet oxygen quenching activity of marine carotenoid fucoxanthin and its metabolites, *J. Agric. Food Chem.* 55 (2007) 8516-8522 <https://doi.org/10.1021/jf071848a>.
- [52] M. Morita, Y. Naito, T. Yoshikawa, E. Niki, Rapid assessment of singlet oxygen-induced plasma lipid oxidation and its inhibition by antioxidants with diphenyl-1-pyrenylphosphine (DPPP), *Anal. Bioanal. Chem.* 408 (2016) 265-270
<https://doi.org/10.1007/s00216-015-9102-7>.
- [53] H. Zhang, Y. Tang, Y. Zhang, S. Zhang, J. Qu, X. Wang, R. Kong, C. Han, Z. Liu, Fucoxanthin: A promising medicinal and nutritional ingredient, *Evid. Based Complement. Alternat. Med.* 2015 (2015) 723515
<https://doi.org/10.1155/2015/723515>.
- [54] H. Nishino, Cancer prevention by carotenoids, *Mutation Res.* 402 (1998) 159-163
[https://doi.org/10.1016/s0027-5107\(97\)00293-5](https://doi.org/10.1016/s0027-5107(97)00293-5).
- [55] T. Nomura, M. Kikuchi, A. Kubodera, Y. Kawakami, Proton-donative antioxidant activity of fucoxanthin with 1,1-diphenyl-2-picrylhydrazyl (DPPH), *Biochem. Mol. Biol. Int.* 42 (1997) 361-370 <https://doi.org/10.1080/15216549700202761>.
- [56] X. Yan, Y. Chuda, M. Suzuki, T. Nagata, Fucoxanthin as the major antioxidant in *Hijikia fusiformis*, a common edible seaweed, *Biosci. Biotechnol. Biochem.* 63 (1999) 605-607 <https://doi.org/10.1271/bbb.63.605>.
- [57] Y. Zhang, H. Fang, Q. Xie, J. Sun, R. Liu, Z. Hong, R. Yi, H. Wu, Comparative evaluation of the radical-scavenging activities of fucoxanthin and its stereoisomers, *Molecules* 19 (2014) 2100-2113
<https://doi.org/10.3390/molecules19022100>.

- [58] M. Takashima, M. Shichiri, Y. Hagihara, Y. Yoshida, E. Niki, Capacity of fucoxanthin for scavenging peroxy radicals and inhibition of lipid peroxidation in model systems, *Free Radic. Res.* 46 (2012) 1406-1412
<https://doi.org/10.3109/10715762.2012.721542>.
- [59] A. Murakami, M. Nakashima, T. Koshihara, T. Maoka, H. Nishino, M. Yano, T. Sumida, O.K. Kim, K. Koshimizu, H. Ohigashi, Modifying effects of carotenoids on superoxide and nitric oxide generation from stimulated leukocytes, *Cancer Let.* 149 (2000) 115-123 [https://doi.org/10.1016/s0304-3835\(99\)00351-1](https://doi.org/10.1016/s0304-3835(99)00351-1).
- [60] S.-J. Heo, S.-C. Ko, S.-M. Kang, H.-S. Kang, J.-P. Kim, S.-J. Kim, S.-J., K.-W. Lee, M.-G. Cho, Y.-J. Jeon, Cytoprotective effect of fucoxanthin isolated from brown algae *Sargassum siliquastrum* against H₂O₂-induced cell damage, *Eur. Food Res. Technol.* 228 (2008) 145-151
<https://doi.org/10.1007/s00217-008-0918-7>.
- [61] J. Zheng, M.J. Piao, Y.S. Keum, H.S. Kim, J.W. Hyun, Fucoxanthin protects cultured human keratinocytes against oxidative stress by blocking free radicals and inhibiting apoptosis, *Biomol. Ther.* 21 (2013) 270-276
<https://doi.org/10.4062/biomolther.2013.030>.
- [62] J. Zeng, Y. Zhang, J. Ruan, Z. Yang, C. Wang, Z. Hong, Z. Zuo, Protective effects of fucoxanthin and fucoxanthinol against tributyltin-induced oxidative stress in HepG2 cells, *Environ. Sci. Pollut. Res. Int.* 25 (2018) 5582-5589
<https://doi.org/10.1007/s11356-017-0661-3>.
- [63] X. Wang, Y.-J. Cui, J. Qi, M.-M. Zhu, T.-L. Zhang, M. Cheng, S.-M. Liu, G.-C. Wang, Fucoxanthin exerts cytoprotective effects against hydrogen peroxide-induced oxidative damage in L02 cells, *Biomed. Res. Int.* 2018 (2018) 108507 <https://doi.org/10.1155/2018/1085073>.
- [64] R.K. Sangeetha, A.N. Bhaskar, A.V. Baskaran, Comparative effects of β -carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats, *Mol. Cell. Biochem.* 331 (2009) 59-67 <https://doi.org/10.1007/s11010-009-0145-y>.
- [65] A.W. Ha, S.J. Na, W.K. Kim, Antioxidant effects of fucoxanthin rich powder in rats fed with high fat diet, *Nutr. Res. Pract.* 7 (2013) 475-480
<https://doi.org/10.4162/nrp.2013.7.6.475>.
- [66] J. Zheng, M.J. Piao, K.C. Kim, C.W. Yao, J.W. Cha, J.W. Hyun, Fucoxanthin enhances the level of reduced glutathione via the Nrf2-mediated pathway in human keratinocytes, *Mar. Drugs* 12 (2014) 4214-4230
<https://doi.org/10.3390/md12074214>.
- [67] N. D'Orazio, E. Gemello, M.A. Gammone, M. de Girolamo, C. Ficoneri, G.

- Riccioni, Fucoxanthin: A treasure from the sea, *Mar. Drugs* 10 (2012) 604-616
<https://doi.org/10.3390/md10030604>.
- [68] M.A. Gammone, N. D'Orazio, Anti-obesity activity of the marine carotenoid fucoxanthin, *Mar. Drugs*, 13 (2015) 2196-2214 <https://doi.10.3390/md13042196>.
- [69] S.R. Kumar, M. Hosokawa, K. Miyashita, Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms, *Mar. Drugs* 11 (2013) 5130-5147 <https://doi.org/10.3390/md11125130>.
- [70] H. Maeda, Nutraceutical effects of fucoxanthin for obesity and diabetes therapy: a review, *J. Oleo Sci.* 64 (2015) 125-132 <https://doi.10.5650/jos.ess14226>.
- [71] L.J. Martin, Fucoxanthin and its metabolite fucoxanthinol in cancer prevention and treatment, *Mar. Drugs* 13 (2015) 4784-4798
<https://doi.org/10.3390/md13084784>.
- [72] K. Miyashita, M. Hosokawa, Health impact of marine carotenoids, *J. Food Bioact.* 1 (2018) 31-40 <https://doi.org/10.31665/JFB.2018.1125>.
- [73] Kh. Muradian, A. Vaiserman, K.-J. Min, V.E. Fraifeld, Fucoxanthin and lipid metabolism: A mini review, *Nutr. Metab. Cardiovasc. Dis.* 25 (2015) 891-897
<https://doi.org/10.1016/j.numecd.2015.05.010>.
- [74] D. Pádua, E. Rocha, D. Gargiulo, A.A. Ramos, Bioactive compounds from brown seaweeds: Phloroglucinol, fucoxanthin and fucoidan as promising therapeutic agents against breast cancer, *Phytochem. Let.* 14 (2015) 91-98
<https://doi.org/10.1016/j.phytol.2015.09.007>.
- [75] J. Peng, J.-P. Yuan, C.-F. Wu, J.-H. Wang, Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: Metabolism and bioactivities relevant to human health, *Mar. Drugs* 9 (2011) 1806-1828
<https://doi.org/10.3390/md9101806>.
- [76] A.M.L. Seca, D.C.G.A. Pinto, Overview on the antihypertensive and anti-obesity effects of secondary metabolites from seaweeds, *Mar. Drugs* 16 (2018) E237
<https://doi.org/10.3390/md16070237>.
- [77] H. Maeda, M. Hosokawa, T. Sashima, K. Funayama, K. Miyashita, Fucoxanthin from edible seaweed, *Undaria pinnatifida*, shows antiobesity effect through UCP1 expression in white adipose tissues, *Biochem. Biophys. Res. Commun.* 332 (2005) 392-397 <https://doi.org/10.1016/j.bbrc.2005.05.002>.
- [78] F. Beppu, M. Hosokawa, M.-J. Yim, T. Shinoda, K. Miyashita, Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by Fucoxanthin via leptin signaling in diabetic/obese KK-*A^y* mice, *Lipids* 48 (2013) 449-455
<https://doi.org/10.1007/s11745-013-3784-4>.

- [79] M. Hosokawa, T. Miyashita, S. Nishikawa, S. Emi, T. Tsukui, F. Beppu, T. Okada, K. Miyashita, Fucoxanthin regulates adipocytokine mRNA expression in white adipose tissue of diabetic/obese KK-Ay mice, *Arch. Biochem. Biophys.* 504 (2010) 17-25 <https://doi.org/10.1016/j.abb.2010.05.031>.
- [80] S.-I. Kang, H.-S. Shin, H.-M. Kim, S.-A. Yoon, S.-W. Kang, J.-H. Kim, H.-C. Ko, S.-J. Kim, *Petalonia binghamiae* extract and its constituent fucoxanthin ameliorate high-fat diet-induced obesity by activating AMP-activated protein kinase, *J. Agric. Food Chem.* 60 (2012) 3389-3395 <https://doi.org/10.1021/jf2047652>.
- [81] H. Maeda, M. Hosokawa, T. Sashima, K. Funayama, K. Miyashita, Effect of medium-chain triacylglycerols on anti-obesity effect of fucoxanthin, *J. Oleo Sci.* 56 (2007) 615-621 <https://doi.org/10.5650/jos.56.615>.
- [82] H. Maeda, M. Hosokawa, T. Sashima, K. Miyashita, Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decrease blood glucose in obese/diabetic KK-*A^y* mice, *J. Agric. Food Chem.* 55 (2007) 7701-7706 <https://doi.org/10.1021/jf071569n>.
- [83] H. Maeda, M. Hosokawa, T. Sashima, K. Murakami-Funayama, K. Miyashita, Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model, *Mol. Med. Rep.* 2 (2009) 897-902 https://doi.org/10.3892/mmr_00000189.
- [84] M.-N. Woo, S.-M. Jeon, Y.C. Shin, M.-K. Lee, M.A. Kang, M.-S. Choi, Anti-obese property of fucoxanthin is partly mediated by altering lipid-regulating enzymes and uncoupling proteins of visceral adipose tissue in mice, *Mol. Nutr. Food Res.* 53 (2009) 1603-1611 <https://doi.org/10.1002/mnfr.200900079>.
- [85] K.-M. Kim, K.-M., S.-M. Kim, D.-Y. Cho, S.-J. Park, N.-S. Joo, The effect of xanthigen on the expression of brown adipose tissue assessed by ¹⁸F-FDG PET, *Yonsei Med. J.* 57 (2016) 1038-1041 <https://doi.org/10.3349/ymj.2016.57.4.1038>.
- [86] S. Saha, U.-G. Gerdtham, P. Johansson, Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases, *Int. J. Environ. Res. Public Health*, 7 (2010) 3150-3195 <https://doi.org/10.3390/ijerph7083150>.
- [87] G.A. Bray, L.A. Tartaglia, Medicinal strategies in the treatment of obesity, *Nature* 404 (2000) 672-677 <https://doi.org/10.1038/35007544>.
- [88] B.B. Lowell, B.M. Spiegelman, Towards a molecular understanding of adaptive thermogenesis, *Nature* 404 (2000) 652-660 <https://doi.org/10.1038/35007527>.
- [89] S. Enerbäck, Brown adipose tissue in humans, *Int. J. Obes.* 34 (2010) S43-S46 <https://doi.org/10.1038/ijo.2010.183>.

- [90] L.P. Kozak, Brown fat and the myth of diet-induced thermogenesis, *Cell. Metab.* 11 (2010) 263-267 <https://doi.org/10.1016/j.cmet.2010.03.009>.
- [91] P. Seale, Transcriptional control of brown adipocyte development and thermogenesis, *Int. J. Obes.* 34 (2010) S17-S22 <https://doi.org/10.1038/ijo.2010.178>.
- [92] J.R. Brestoff, D. Artis, Immune regulation of metabolic homeostasis in health and disease, *Cell* 161 (2015) 146-160 <https://doi.org/10.1016/j.cell.2015.02.022>.
- [93] M. Harms, P. Seale, Brown and beige fat: development, function and therapeutic potential, *Nature Med.* 19 (2013) 1252-1263 <https://doi.org/10.1038/nm.3361>.
- [94] E. Mueller, Browning and graying: novel transcriptional regulators of brown and beige fat tissues and aging, *Front. Endocrinol. (Lausanne)* 7 (2016) 19 <https://doi.org/10.3389/fendo.2016.00019>.
- [95] X. Hu, N. Tao, X. Wang, J. Xiao, M. Wang, Marine-derived bioactive compounds with anti-obesity effect: A review, *J. Functional Foods* 21 (2016) 372-387 <https://doi.org/10.1016/j.jff.2015.12.006>.
- [96] S. Nishikawa, M. Hosokawa, K. Miyashita, Fucoxanthin promotes translocation and induction of glucose transporter 4 in skeletal muscles of diabetic/obese KK-A(y) mice, *Phytomedicine* 19 (2012) 389-394 <https://doi.org/10.1016/j.phymed.2011.11.001>.
- [97] M.-T. Wu, H.-N. Chou, C.-J. Huang, Dietary fucoxanthin increases metabolic rate and upregulated mRNA expressions of the PGC-1alpha network, mitochondrial biogenesis and fusion genes in white adipose tissues of mice, *Mar. Drugs* 12 (2014) 964-9824 <https://doi.org/10.3390/md12020964>.
- [98] M.-N. Woo, S.-M. Jeon, H.-J. Kim, M.-K. Lee, S.-K. Shin, Y.C. Shin, Y.-B. Park, M.-S. Choi, Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice, *Chem. Biol. Interact.* 186 (2010) 316-322 <https://doi.org/10.1016/j.cbi.2010.05.006>.
- [99] H.J. Park, M.K. Lee, Y.B. Park, Y.C. Shin, M.S. Choi, Beneficial effects of *Undaria pinnatifida* ethanol extract on diet-induced-insulin resistance in C57BL/6J mice, *Food Chem. Toxicol.* 49 (2011) 727-733 <https://doi.org/10.1016/j.fct.2010.11.032>.
- [100] Y. Lee, S. Hu, Y.-K. Park, J.-Y. Lee, Health benefits of carotenoids: A role of carotenoids in the prevention of non-alcoholic fatty liver disease, *Prev. Nutr. Food Sci.* 24 (2019) 103-113 <https://doi.org/10.3746/pnf.2019.24.2.103>.
- [101] H. Maeda, M. Hosokawa, T. Sashima, N. Takahashi, T. Kawada, K. Miyashita,

Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells, *Int. J. Mol. Med.* 18 (2006) 147-152
<https://doi.org/10.3892/ijmm.18.1.147>.

[102] M.J. Yim, M. Hosokawa, Y. Mizushima, H. Yoshida, Y. Saito, K. Miyashita, Suppressive effects of amarouciaxanthin A on 3T3-L1 adipocyte differentiation through down-regulation of PPAR γ and C/EBP α mRNA expression, *J. Agric. Food Chem.* 59 (2011) 1646-1652 <https://doi.org/10.1021/jf103290f>.

[103] S.I. Kang, H.C. Ko, H.S. Shin, H.M. Kim, Y.S. Hong, N.H. Lee, S.J. Kim, Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes, *Biochem. Biophys. Res. Commun.* 409 (2011) 769-774 <https://doi.org/10.1016/j.bbrc.2011.05.086>.

[104] Y. Okada, M. Nakai, H. Maeda, M. Hosokawa, T. Sashima, K. Miyashita, Suppressive effect of neoxanthin on the differentiation of 3T3-L1 adipose cells, *J. Oleo Sci.* 57 (2008) 345-351 <https://doi.org/10.5650/jos.57.345>.

[105] G. Bruno, A. Landi, Epidemiology and costs of diabetes, *Transplant. Proc.* 43 (2011) 327-329 <https://doi.org/10.1016/j.transproceed.2010.09.098>.

[106] C.L. Leibson, D.F. Williamson, L.J. Melton, P.J. Palumbo, S.A. Smith, J.E. Ransom, P.L. Schilling, K.M.V. Narayan, Temporal trends in BMI among adults with diabetes, *Diabetes Care* 24 (2001) 1584-1589
<https://doi.org/10.2337/diacare.24.9.1584>.

[107] S.E. Shoelson, J. Lee, A.B. Goldfine, Inflammation and insulin resistance, *J. Clin. Invest.* 116 (2006) 1793-1801 <https://doi.org/10.1172/JCI29069>.

[108] S. Huang, M.P. Czech, The GLUT4 glucose transporter, *Cell Metab.* 5 (2007) 237-252 <https://doi.org/10.1016/j.cmet.2007.03.006>.

[109] E.J. Henriksen, R.E. Bourey, K.J. Rodnick, L. Koranyi, M.A. Permutt, J.O. Holloszy, Glucose transporter protein content and glucose transport capacity in rat skeletal muscles, *Am. J. Physiol.* 259 (1999) E593-E598
<https://doi.org/10.1152/ajpendo.1990.259.4.E593>.

[110] A. Bonen, PGC-1 α -induced improvements in skeletal muscle metabolism and insulin sensitivity, *Appl. Physiol. Nutr. Metab.* 34 (2009) 307-314
<https://doi.org/10.1139/H09-008>.

[111] L.F. Michael, Z. Wu, R.B. Cheatham, P. Puigserver, G. Adelmant, J.J. Lehman, D.P. Kelly, B.M. Spiegelman, Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1, *Proc. Natl. Acad. Sci. U.S.A.* 98 (2001) 3820-3825
<https://doi.org/10.1073/pnas.061035098>.

- [112] C. Galasso, C. Corinaldesi, C. Sansone, Carotenoids from marine organisms: Biological functions and industrial applications, *Antioxidants* (Basel) 6 (2017) E96 <https://doi.org/10.3390/antiox6040096>.
- [113] J. Okuzumi, H. Nishino, M. Murakoshi, A. Iwashima, Y. Tanaka, T. Yamane, Y. Fujita, T. Takahashi, Inhibitory effects of fucoxanthin, a natural carotenoid, on N-myc expression and cell cycle progression in human malignant tumor cells, *Cancer Lett.* 55 (1990) 75-81 [https://doi.org/10.1016/0304-3835\(90\)90068-9](https://doi.org/10.1016/0304-3835(90)90068-9).
- [114] M. Hosokawa, S. Wanezaki, K. Miyauchi, H. Kurihara, H. Kohno, J. Kawabata, K. Takahashi, Apoptosis-inducing effect of fucoxanthin on human leukemia cell HL-60, *Food Sci. Technol. Res.* 5 (1999) 243-246 <https://doi.org/10.3136/fstr.5.243>.
- [115] M. Hosokawa, M. Kudo, H. Maeda, H. Kohno, T. Tanaka, K. Miyashita, Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARgamma ligand, troglitazone, on colon cancer cells, *Biochim. Biophys. Acta* 1675 (2004) 113-119 <https://doi.org/10.1016/j.bbagen.2004.08.012>.
- [116] E. Kotake-Nara, A. Asai, A. Nagao, Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells, *Cancer Lett.* 220 (2005) 75-84 <https://doi.org/10.1016/j.canlet.2004.07.048>.
- [117] E. Kotake-Nara, T. Sugawara, A. Nagao, Antiproliferative effect of neoxanthin and fucoxanthin on cultured cells, *Fisheries Sci.* 71 (2005) 459-461 <https://doi.org/10.1111/j.1444-2906.2005.00986.x>.
- [118] E. Kotake-Nara, M. Kushihiro, H. Zhang, T. Sugawara, K. Miyashita, A. Nagao, Carotenoids affect proliferation of human prostate cancer cells, *J. Nutr.* 131 (2001) 3303-3306 <https://doi.org/10.1093/jn/131.12.3303>.
- [119] K.-N. Kim, G. Ahn, S.-J. Heo, S.-M. Kang, M.-C. Kang, H.-M. Yang, D. Kim, S.W. Roh, S.-K. Kim, B.-T. Jeon, P.-J. Park, W.-K. Jung, Y.-J. Jeon, Inhibition of tumor growth *in vitro* and *in vivo* by fucoxanthin against melanoma B16F10 cells, *Environ. Toxicol. Pharmacol.* 35 (2013) 39-46 <https://doi.org/10.1016/j.etap.2012.10.002>.
- [120] J. Okuzumi, T. Takahashi, T. Yamane, Y. Kitao, M. Inagake, K. Ohya, H. Nishino, Y. Tanaka, Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N'-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis, *Cancer Lett.* 68 (1993) 159-168 [https://doi.org/10.1016/0304-3835\(93\)90142-v](https://doi.org/10.1016/0304-3835(93)90142-v).
- [121] H. Nishino, Cancer chemoprevention by natural carotenoids and their related compounds, *J. Cell. Biochem. Suppl.* 22 (1993) 231-235 <https://doi.org/10.1002/jcb.240590829>.

- [122] J. Wang, S. Chen, S. Xu, X. Yu, D. Ma, X. Hu, X. Cao, *In vivo* induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice, *Mar. Drugs* 10 (2012) 2055-2068 <https://doi.org/10.3390/md10092055>.
- [123] S.K. Das, T. Hashimoto, M. Baba, H. Nishino, A. Komoto, K. Kanazawa, Japanese kelp (kombu) extract suppressed the formation of aberrant crypt foci in azoxymethane challenged mouse colon, *J. Clin. Biochem. Nutr.* 38 (2006) 119-125 <https://doi.org/10.3164/jcbtn.38.119>.
- [124] J.M. Kim, S. Araki, D.J. Kim, C.B. Park, N. Takasuka, H. Baba-Toriyama, T. Ota, Z. Nir, F. Khachik, N. Shimidzu, Y. Tanaka, T. Osawa, T. Uraji, M. Murakoshi, H. Nishino, H. Tsuda, Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-dimethylhydrazine initiation, *Carcinogenesis* 19 (1998) 81-85 <https://doi.org/10.1093/carcin/19.1.81>.
- [125] S.Z. Moghadamtousi, H. Karimian, R. Khanabdali, M. Razavi, M. Firoozinia, K. Zandi, H.A. Kadir, Anticancer and antitumor potential of fucoidan and fucoxanthin, two main metabolites isolated from brown algae, *Nutr. Metab. Cardiovasc. Dis.* 25 (2015) 891-897 <https://doi.org/10.1155/2014/768323>.
- [126] K. Takahashi, M. Hosokawa, H. Kasajima, K. Hatanka, K. Kudo, N. Shimoyama, K. Miyashita, K., 2015. Anticancer effects of fucoxanthin and fucoxanthinol on colorectal cancer cell lines and colorectal cancer tissues, *Oncol. Let.* 10 (2015) 1463-1467 <https://doi.org/10.3892/ol.2015.3380>.
- [127] M. Terasaki, H. Maeda, K. Miyashita, T. Tanaka, S. Miyamoto, M. Mutoh, A marine bio-functional lipid, fucoxanthinol, attenuates human colorectal cancer stem-like cell tumorigenicity and sphere formation, *J. Clin. Biochem. Nutr.* 61 (2017) 25-32 <https://doi.org/10.3164/jcbtn.16-112>.
- [128] M. Terasaki, M. Mima, S. Ludoh, T. Endo, H. Maeda, J. Hamada, K. Osada, K. Miyashita, M. Mutoh, Glycine and succinic acid are effective indicators of the suppression of epithelial-mesenchymal transition by fucoxanthinol in colorectal cancer stem-like cells, *Oncology Rep.* 40 (2018) 414-424 <https://doi.org/10.3892/or.2018.6398>.
- [129] M. Terasaki, H. Maeda, K. Miyashita, M. Mutoh, Induction of anoikis in human colorectal cancer cells by fucoxanthinol, *Nutr. Cancer* 69 (2017) 1043-1052 <https://doi.org/10.1080/01635581.2017.1339814>.
- [130] M. Terasaki, T. Iida, F. Kikuchi, K. Tamura, T. Endo, Y. Kuramitsu, T. Tanaka, H. Maeda, K. Miyashita, M. Mutoh, Fucoxanthin potentiates anoikis in colon mucosa and prevents carcinogenesis in AOM/DSS model mice, *J. Nutr.*

- Biochem. 64 (2019) 198-205 <https://doi.org/10.1016/j.jnutbio.2018.10.007>.
- [131] M. Terasaki, N. Matsumoto, R. Hashimoto, T. Endo, H. Maeda, J. Hamada, K. Osada, K. Miyashita, M. Mutoh, Fucoxanthin administration delays occurrence of tumors in xenograft mice by colonospheres, with and anti-tumor predictor of glycine, J. Clin. Biochem. Nutr. 64 (2019) 52-58 <https://doi.org/10.3164/jcbtn.18-45>.
- [132] M. Terasaki, S. Masaka, C. Fukada, M. Houzaki, T. Endo, T. Tanaka, H. Maeda, K. Miyashita, M. Mutoh, Salivary glycine is a significant predictor for the attenuation of polyp and tumor microenvironment formation by fucoxanthin in AOM/DSS mice, In Vivo 33 (2019) 365-374 <https://doi.org/10.21873/invivo.11483>.
- [133] M.A. Gammone, G. Riccioni, N. D'Orazio, Carotenoids: potential allies of cardiovascular health? Food Nutr. Res. 59 (2015) 26762 <https://doi.org/10.3402/fnr.v59.26762>.
- [134] P.-A. Hwang, N.N. Phan, W.-J. Lu, B.T.N. Hieu, Y.-C. Lin, Low-molecular-weight fucoidan and high-stability fucoxanthin from brown seaweed exert prebiotics and anti-inflammatory activities in Caco-2 cells, Food. Nutr. Res. 60 (2016) 32033 <https://doi.org/10.3402/fnr.v60.32033>.
- [135] R.C. Robertson, F. Guihéneuf, B. Bahar, M. Schmid, D.B. Stengel, G.F. Fitzgerald, R.P. Ross, C. Stanton, The anti-inflammatory effect of algae-derived lipid extract on lipopolysaccharide (LPS)-stimulated human THP-1 macrophages, Mar. Drugs, 13 (2015) 5402-5424 <https://doi.org/10.3390/md13085402>.
- [136] J. Su, K. Guo, M. Huang, Y. Liu, J. Zhang, L. Sun, D. Li, K.-L. Pang, G. Wang, L. Chen, Z. Liu, Y. Chen, Q. Chen, L. Huang, Fucoxanthin, a marine xanthophyll isolated from *Conticribra weissflogii* ND-8: Preventive anti-inflammatory effect in a mouse model of sepsis, Front. Pharmacol. 10 (2019) 906 <https://doi.org/10.3389/fphar.2019.00906>.
- [137] K.-N. Kim, S.-J. Heo, W.-J. Yoon, S.-M. Kang, G. Ahn, T.-H. Yi, Y.-J. Jeon, Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF- κ B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages, Eur. J. Pharmacol. 649 (2010) 369-375 <https://doi.org/10.1016/j.ejphar.2010.09.032>.
- [138] C.-P. Tan, Y.-H. Hou, First evidence for the anti-inflammatory activity of fucoxanthin in high-fat-diet-induced obesity in mice and the antioxidant functions in PC12 cells, Inflammation 37 (2014) 443-450 <https://doi.org/10.1007/s10753-013-9757-1>.

- [139] A. Rodríguez-Luna, J. Ávila-Román, H. Oliveira, V. Motilva, E. Talero, Fucoxanthin and rosmarinic acid combination has anti-inflammatory effects through regulation of NLRP3 inflammasome in UVB-exposed HaCaT keratinocytes, *Mar. Drugs* 17 (2019) E451 <https://doi.org/10.3390/md17080451>.
- [140] S.-J. Chen, C.-J. Lee, T.-B. Lin, H.-Y. Peng, H.-J. Liu, Y.-S. Chen, K.-W. Tseng, Protective effects of Fucoxanthin on ultraviolet B-induced corneal denervation and inflammatory pain in a rat model, *Mar. Drugs* 17 (2019) E152 <https://doi.org/10.3390/md17030152>.
- [141] K. Ikeda, A. Kitamura, H. Machida, M. Watanabe, H. Negishi, J. Hiraoka, T. Nakano, Effect of *Undaria pinnatifida* on the development of cerebrovascular diseases in stroke prone spontaneously hypertensive rats, *Clin. Exp. Pharmacol. Physiol.* 30 (2003) 44-48 <https://doi.org/10.1046/j.1440-1681.2003.03786.x>.
- [142] T. Tsukui, K. Konno, M. Hosokawa, H. Maeda, T. Sashima, K. Miyashita, Fucoxanthin and fucoxanthinol enhance the amount of docosahexaenoic acid in the liver of KKAY obese/diabetic mice, *J. Agric. Biol. Chem.* 55 (2007) 5025-5029 <https://doi.org/10.1021/jf070110q>.
- [143] K. Yamagata, Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease, *Lipids Health Dis.* 16 (2017) 118 <https://doi.org/10.1186/s12944-017-0514-6>.
- [144] J. Backes, D. Anzalone, D. Hilleman, J. Catini, The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia, *Lipids Health Dis.* 15 (2016) 118 <https://doi.org/10.1186/s12944-016-0286-4>.
- [145] F. Fernandes, M. Barbosa, D.M. Pereira, I. Sousa-Pinto, P. Valentão, I.C. Azevedo, P.B. Andrade, P.B., 2018. Chemical profiling of edible seaweed (Ochrophyta) extracts and assessment of their in vitro effects on cell-free enzyme systems and on the viability of glutamate-injured SH-SY5Y cells, *Food Chem. Toxicol.* 116(Pt B) (2018) 196-206 <https://doi.org/10.1016/j.fct.2018.04.033>.
- [146] J. Yu, J.-J. Lin, R. Yu, S. He, Q.-W. Wang, W. Cui, J.-R. Zhang, Fucoxanthin prevents H₂O₂-induced neuronal apoptosis via concurrently activating the PI3-K/Akt cascade and inhibiting the ERK pathway, *Food Nutr. Res.* 61 (2017) 1304678 <https://doi.org/10.1080/16546628.2017.1304678>.
- [147] M. Alghazwi, S. Smid, I. Musgrave, W. Zhang, In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (A β ₁₋₄₂) toxicity and aggregation, *Neurochem. Int.* 124 (2019) 215-224 <https://doi.org/10.1016/j.neuint.2019.01.010>.
- [148] J. Lin, J. Yu, J. Zhao, K. Zhang, J. Zheng, J. Wang, C. Huang, J. Zhang, X. Yan,

- W.H. Gerwick, Q. Wang, W. Cui, S. He, Fucoxanthin, a marine carotenoid, attenuates β -amyloid oligomer-induced neurotoxicity possibly via regulating the PI3K/Akt and the ERK pathways in SH-SY5Y cells, *Oxid. Med. Cell Longev.* 2017 (2017) 6792543 <https://doi.org/10.1155/2017/6792543>.
- [149] S. Xiang, F. Liu, J. Lin, H. Chen, C. Huang, L. Chen, Y. Zhou, L. Ye, K. Zhang, J. Jin, J. Zhen, C. Wang, S. He, Q. Wang, W. Cui, J. Zhang, Fucoxanthin inhibits β -amyloid assembly and attenuates β -amyloid oligomer-induced cognitive impairments, *J. Agric. Food Chem.* 65 (2017) 4092-4102 <https://doi.org/10.1021/acs.jafc.7b00805>.
- [150] R. Pangestuti, T.-S. Vo, D.-H. Ngo, S.-K. Kim, Fucoxanthin ameliorates inflammation and oxidative responses in microglia, *J. Agric. Food Chem.* 61 (2013) 3876-3883 <https://doi.org/10.1021/jf400015k>.
- [151] L. Hu, W. Chen, F. Tian, C. Yuan, H. Wang, H. Yue, Neuroprotective role of fucoxanthin against cerebral ischemic/reperfusion injury through activation of Nrf2/HO-1 signaling, *Biomed. Pharmacother.* 106 (2018) 1484-1489 <https://doi.org/10.1016/j.biopha.2018.07.088>.
- [152] L. Zhang, H. Wang, Y. Fan, Y. Gao, X. Li, Z. Hu, K. Ding, Y. Wang, X. Wang, Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2-ARE and Nrf2-autophagy pathways, *Sci. Rep.* 7 (2017) 46763 <https://doi.org/10.1038/srep46763>.
- [153] J. Lakey-Beitia, D.J. Kumar, M.L. Hegde, K.S. Rao, Carotenoids as novel therapeutic molecules against neurodegenerative disorders: Chemistry and molecular docking analysis, *Int. J. Mol. Sci.* 20 (2019) E5553 <https://doi.org/10.3390/ijms20225553>.
- [154] P. Paudel, S.H. Seong, H.A. Jung, J.S. Choi, Characterizing fucoxanthin as a selective dopamine D3/D4 receptor agonist: Relevance to Parkinson's disease, *Chem. Biol. Interact.* 310 (2019) 1087579 <https://doi.org/10.1016/j.cbi.2019.108757>.
- [155] H.A. Jung, M.Y. Ali, R.J. Choi, H.O. Jeong, H.Y. Chung, J.S. Choi, Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae *Undaria pinnatifida* and *Ecklonia stolonifera*, *Food Chem. Toxicol.* 89 (2016) 104-111 <https://doi.org/10.1016/j.fct.2016.01.014>.
- [156] M. Terasaki, A. Hirose, B. Narayan, Y. Baba, C. Kawagoe, H. Yasui, N. Saga, M. Hosokawa, K. Miyashita, Evaluation of recoverable functional lipid components with special reference to fucoxanthin and fucosterol contents of several brown seaweeds of Japan, *J. Phyco.* 45 (2009) 974-980

<https://doi.org/10.1111/j.1529-8817.2009.00706.x>.

- [157] M. Nomura, H. Kamogawa, E. Susanto, C. Kawagoe, H. Yasui, N. Saga, M. Hosokawa, K. Miyashita, Seasonal variations of total lipids, fatty acid composition, and fucoxanthin contents of *Sargassum horneri* (Turner) and *Cystoseira hakodatensis* (Yendo) from the northern seashore of Japan, *J. Appl. Phycol.* 25 (2013) 1159-1169 <https://doi.org/10.1007/s10811-012-9934-x>.
- [158] M. Terasaki, C. Kawagoe, A. Ito, H. Kumon, B. Narayan, M. Hosokawa, K. Miyashita, Spatial and seasonal variations in the biofunctional lipid substances (fucoxanthin and fucosterol) of the laboratory-grown edible Japanese seaweed (*Sargassum horneri* Turner) cultured in the open sea, *Saudi J. Biol. Sci.* 24 (2017) 1475-1482 <https://doi.org/10.1016/j.sjbs.2016.01.009>.
- [159] A. Delbrut, P. Albina, T. Lapierre, R. Pradelles, E. Dubreucq, Fucoxanthin and polyunsaturated fatty acids co-extraction by a green process, *Molecules* 23 (2018) E874 <https://doi.org/10.3390/molecules23040874>.
- [160] I. Jaswir, D. Noviendri, H.M. Salleh, M. Taher, K. Miyashita, Isolation of fucoxanthin and fatty acids analysis of *Padina australis* and cytotoxic effect of fucoxanthin on human lung cancer (H1299) cell lines, *Afr. J. Biotechnol.* 10 (2011) 18855-18862 <https://doi.org/10.5897/AJB11.2765>.
- [161] K. Kanazawa, Y. Ozaki, T. Hashimoto, S.K. Das, S. Matsushita, M. Hirano, T. Okada, A. Komoto, N. Mori, M. Nakatsuka, Commercial scale preparation of biofunctional fucoxanthin from waste parts of brown sea algae *Laminaria japonica*, *Food Sci. Technol. Res.* 14 (2008) 573-582 <https://doi.org/10.3136/fstr.14.573>.
- [162] H. Kanda, Y. Kamo, S. Machmudah, Wahyudiono, M. Goto, Extraction of fucoxanthin from raw macroalgae excluding drying and cell wall disruption by liquefied dimethyl ether, *Mar. Drugs* 12 (2014) 2383-2396 <https://doi.org/10.3390/md12052383>.
- [163] S.M. Kim, Y.J. Jung, O.N. Kwon, K.H. Cha, B.H. Um, D. Chung, C.H. Pan, A potential commercial source of fucoxanthin extracted from the microalga *Phaeodactylum tricornutum*, *Appl. Biochem. Biotechnol.* 166 (2012) 1843-1855 <https://doi.org/10.1007/s12010-012-9602-2>.
- [164] D. Noviendri, I. Jaswir, H.M. Salleh, M. Taher, K. Miyashita, N. Ramli, Fucoxanthin extraction and fatty acid analysis of *Sargassum binderi* and *S. duplicatum*, *J. Med. Plant Res.* 5 (2011) 2405-2412.
- [165] M.P. Sudhakar, J.S. Ananthalakshmi, J.S., B.B. Nair, Extraction, purification and study on antioxidant properties of fucoxanthin from brown seaweeds, *J. Chem.*

- Pharm. Res. 5 (2013) 169-175.
- [166] S. Xia, K. Wang, L. Wan, A. Li, Q. Hu, C. Zhang, Production, characterization and antioxidant activity of fucoxanthin from the marine diatom *Odontella aurita*, Mar. Drugs 11 (2013) 2667-2681 <https://doi.org/10.3390/md11072667>.
- [167] Y.F. Shang, S.M. Kim, W.J. Lee, B.H. Um, Pressurized liquid method for fucoxanthin extraction from *Eisenia bicyclis* (Kjellman) Setchell, J. Biosci. Bioeng. 111 (2011) 237-241 <https://doi.org/10.1016/j.jbiosc.2010.10.008>.
- [168] M.J. Billakanti, O. Catchpole, T. Fenton, K. Mitchell, Enzyme assisted extraction of fucoxanthin and lipids containing polyunsaturated fatty acids from *Undaria pinnatifida* using dimethyl ether and ethanol, Process Biochem. 48 (2013) 1999-2008 <https://doi.org/10.1016/j.procbio.2013.09.015>.
- [169] E.M. Balboa, A. Moure, H. Domínguez, Valorization of *Sargassum muticum* biomass according to the biorefinery concept, Mar. Drugs 13 (2015) 3745-3760 <https://doi.org/10.3390/md13063745>.
- [170] E. Conde, A. Moure, H. Domínguez, Supercritical CO₂ extraction of fatty acids, phenolics and fucoxanthin from freeze-dried *Sargassum muticum*, J. Appl. Phycol. 27 (2015) 957-964 2015 <https://doi.org/10.1007/s10811-014-0389-0>.
- [171] A.T. Quitain, T. Kai, M. Sasaki, M. Goto, Supercritical carbon dioxide extraction of fucoxanthin from *Undaria Pinnatifida*, J. Agric. Food Chem. 61 (2013) 5792-5797 <https://doi.org/10.1021/jf400740p>.
- [172] M.K. Roh, M.S. Uddin, B.S. Chun, Extraction of fucoxanthin and polyphenol from *Undaria pinnatifida* using supercritical carbon dioxide with co-solvent, Biotechnol. Bioproc. Eng. 13 (2008) 724-729 <https://doi.org/10.1007/s12257-008-0104-6>.
- [173] S.P. Sivagnanam, S. Yin, J.H. Choi, Y.B. Park, H.C. Woo, B.S. Chun, Biological properties of fucoxanthin in oil recovered from two brown seaweeds using supercritical CO₂ extraction, Mar. Drugs 13 (2015) 3422-3442 <https://doi.org/10.3390/md13063422>.
- [174] P. Adadi, N.V. Barakova, E.F. Krivoshapkina, Selected methods of extracting carotenoids, characterization, and health concerns: A review, J. Agric. Food Chem. 66 (2018) 5925-5947 <https://doi.org/10.1021/acs.jafc.8b01407>.
- [175] F. Chemat, M.A. Vian, G. Cravotto, Green extraction of natural products: Concept and principles, Int. J. Mol. Sci. 13 (2012) 8615-8627 <https://doi.org/10.3390/ijms13078615>.
- [176] M.N. Rammuni, T.U. Ariyadasa, P.H.V. Nimarshana, R.A. Attalage, Comparative assessment on the extraction of carotenoids from microalgal sources: Astaxanthin

- from *H. pluvialis* and β -carotene from *D. salina*, Food Chem. 277 (2019) 128-134
<https://doi.org/10.1016/j.foodchem.2018.10.066>.
- [177] J. Pu, P.J. Bechtel, S. Sathivel, Extraction of shrimp astaxanthin with flaxseed oil: Effects on lipid oxidation and astaxanthin degradation rates, Biosyst. Eng. 107 (2010) 364-371 <https://doi.org/10.1016/j.biosystemseng.2010.10.001>.
- [178] W.A.C.(K.) Koekkoek, V. Panteleon, V., A.R.H. van Zanten, Current evidence on ω -3 fatty acids in enteral nutrition in the critically ill: A systematic review and meta-analysis, Nutrition, 59 (2019) 56-68
<https://doi.org/10.1016/j.nut.2018.07.013>.
- [179] D.R. Tocher, M.B. Betancor, M. Sprague, R.E. Olsen, J.A. Napier, Omega-3 long-chain polyunsaturated fatty acids, EPA and DHA: Bridging the gap between supply and demand, Nutrients, 11 (2019) 89
<https://doi.org/10.3390/nu11010089>.
- [180] T. Aoyama, N. Nosaka, M. Kasai, Research on the nutritional characteristics of medium-chain fatty acids, J. Med. Investig. 54 (2007) 385-388
<https://doi.org/10.2152/jmi.54.385>.
- [181] M.F. McCarty, J.J. DiNicolantonio, Lauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicity, Open Heart Journal, 3 (2016) e000467
<https://doi.org/10.1136/openhrt-2016-000467>.
- [182] H. Takeuchi, S. Sekine, K. Kojima, T. Aoyama, The application of medium-chain fatty acids: edible oil with a suppressing effect on body fat accumulation, Asia Pac. J. Clin. Nutr. 17 (2008) 320-323.
- [183] V. Francisco, C. Ruiz-Fernández, V. Lahera, F. Lago, J. Pino, L. Skaltsounis, M.A. González-Gay, A. Mobasher, R. Gómez, M. Scotece, O. Gualillo, Natural molecules for healthy lifestyles: Oleocanthal from extra virgin olive oil, J. Agric. Food Chem. 67 (2019) 3845-3853 <https://doi.org/10.1021/acs.jafc.8b06723>.
- [184] V. Summerhill, V. Karagodin, A. Grechko, V. Myasoedova, A. Orekhov, A., 2018. Vasculoprotective role of olive oil compounds via modulation of oxidative stress in atherosclerosis, Front. Cardiovasc. Med. 5 (2018) 188
<https://doi.org/10.3389/fcvm.2018.00188>.
- [185] A.D. Handayani, Sutrisno, N. Indraswati, S. Ismadji, Extraction of astaxanthin from giant tiger (*Panaeus monodon*) shrimp waste using palm oil: Studies of extraction kinetics and thermodynamic, Bioresour. Technol. 99 (2008) 4414-4419
<https://doi.org/10.1016/j.biortech.2007.08.028>.
- [186] B.R. Parjikolaie, R.B. El-Houri, X.C. Fretté, K.V. Christensen, Influence of green

- solvent extraction on carotenoid yield from shrimp (*Pandalus borealis*)
processing waste, J. Food Eng. 155 (2015) 22-28
<https://doi.org/10.1016/j.jfoodeng.2015.01.009>.
- [187] N.M. Sachindra, N.S. Mahendrakar, Process optimization for extraction of
carotenoids from shrimp waste with vegetable oils, Bioresour. Technol. 96 (2005)
1195-1200 <https://doi.org/10.1016/j.biortech.2004.09.018>.
- [188] F. Shahidi, J. Synowiecki, J., 1991. Isolation and characterization of nutrients and
value added products from snow crab (*Chionoecetes opilio*) and shrimp (*Pandalus
borealis*) processing discards, J. Agric. Food Chem. 39 (1991) 1527-1532
<https://doi.org/10.1021/jf00008a032>.
- [189] H.-M. Chen, S. P. Meyers, Extraction of astaxanthin pigment from crawfish waste
using a soy oil process, J. Food Sci. 47 (1982) 892-896
<https://doi.org/10.1111/j.1365-2621.1982.tb12739.x>.
- [190] H.-M. Chen, S. P. Meyers, A rapid quantitative method for determination of
astaxanthin pigment concentration in oil extracts, J. Am. Oil Chem. Soc. 61
(1984) 1045-1047 <https://doi.org/10.1007/BF02636215>.
- [191] T.R. Omara-Alwala, H.-M. Chen, Y.M. Ito, K.L. Simpson, S.P. Meyers, 1985.
Carotenoid pigment and fatty acid analysis of crawfish oil extracts, J. Agric. Food
Chem. 33 (1985) 260-263 <https://doi.org/10.1021/jf00062a026>.
- [192] C.D. Kang, S.J. Sim, Direct extraction of astaxanthin from Haematococcus
culture using vegetable oils, Biotechnol. Lett. 30 (2008) 441-444
<https://doi.org/10.1007/s10529-007-9578-0>.
- [193] A.R. Rao, R. Sarada, G.A. Ravishankar, Stabilization of astaxanthin in edible oils
and its use as an antioxidant, J. Sci. Food Agric. 87 (2007) 957-965
<https://doi.org/10.1002/jsfa.2766>.
- [194] Y. Li, A.S. Fabiano-Tixier, V. Tomao, G. Cravotto, F. Chemat, Green
ultrasound-assisted extraction of carotenoids based on the bio-refinery concept
using sunflower oil as an alternative solvent, Ultrason. Sonochem. 20 (2013)
12-18 <https://doi.org/10.1016/j.ultsonch.2012.07.005>.
- [195] K. Teramukai, S. Kakui, F. Beppu, M. Hosokawa, K. Miyashita, Effective
extraction of carotenoids from brown seaweeds and vegetable leaves with edible
oils, Innov. Food Sci. Emerg. Technol. 60 (2020) (in press)
<https://doi.org/10.1016/j.ifset.2020.102302>.

Figure legends

- 1224 Fig. 1. Antioxidant activity of Fx.
- 1225 Fig. 2. Major biological impact of Fx.
- 1226 Fig. 3. Major possible mechanism for the anti-obesity effect of Fx.

Fig. 1

Fig. 2

Fig. 3